ALA Launches Spotlight Series in Partnership with Symyx Technologies and Thermo Fisher Scientific
News Jul 25, 2007
The Association for Laboratory Automation has launched the ALA Spotlight Series, a scientific-based educational program created in partnership with industry leaders Symyx Technologies and Thermo Fisher Scientific.
A recent ALA industrial automation survey indicated that the speed, reliability and function of laboratory automation tools are no longer the most limiting factor in the use of such automation. The current limiting factors have to do with the challenge of doing science with such tools, such as developing and validating new automated protocols.
In response to this information, ALA put together a series of workshops that focus specifically on the practical matters and challenges of putting automation to work to do good science.
The ALA Spotlight Series offers complimentary one-day scientific, results-based educational programs that highlight putting automation to work. Driven by ALA's Scientific Faculty Advisors, the series will feature in-depth sessions and direct participant-presenter engagement.
Participants will benefit from the knowledge, insights and experiences of the ALA-member presenters regarding the successes and challenges of transfer and deployment of automation and technologies in the laboratory.
ALA President Reinhold Schafer, Fachhochschule Wiesbaden, Germany, feels the time is right for this type of program. “We believe putting together a high-caliber educational program, combined with complimentary registration, will help promulgate the successful application of laboratory automation, which is part of our mission. With the support and involvement of our two industry partners, we anticipate this program will be an immediate success,” he said.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.